Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value
-
Shares outstanding
-
83.1M
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
4.88M
-
Shares change
-
+1.01M
-
Total reported value, excl. options
-
$11.2M
-
Value change
-
+$2.46M
-
Put/Call ratio
-
0.71
-
Number of buys
-
26
-
Number of sells
-
-17
-
Price
-
$2.29
Significant Holders of Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) as of Q4 2023
53 filings reported holding CKPT - Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value as of Q4 2023.
Checkpoint Therapeutics, Inc. - Common Stock, $0.0001 Par Value (CKPT) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.88M shares
of 83.1M outstanding shares and own 5.87% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (2.43M shares), VANGUARD GROUP INC (548K shares), GEODE CAPITAL MANAGEMENT, LLC (174K shares), BlackRock Inc. (167K shares), RENAISSANCE TECHNOLOGIES LLC (166K shares), B. Riley Wealth Advisors, Inc. (163K shares), OSAIC HOLDINGS, INC. (163K shares), D. E. Shaw & Co., Inc. (141K shares), PVG ASSET MANAGEMENT CORP (115K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (95.1K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.